Center Advisors, Dissemination & Implementation Core
Bruce R. Schackman, PhD, MBA
Bruce R. Schackman, PhD, MBA
Saul P. Steinberg Distinguished Professor; Executive Vice Chair, Department of Population Health Sciences; Director, Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH)
Dr. Schackman is the Director of CHERISH – The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV – a multi-institutional Center of Excellence, funded by the National Institute on Drug Abuse (P30DA040500). CHERISH is a collaboration among researchers at Weill Cornell Medicine, Boston Medical Center, the University of Pennsylvania Leonard Davis Institute of Health Economics, and the University of Miami Miller School of Medicine. Dr. Schackman is the Saul P. Steinberg Distinguished Professor of Healthcare Policy & Research at Weill Cornell, where he conducts economic evaluations of the comparative effectiveness of health interventions alongside clinical trials and cohort studies, cost-effectiveness and comparative effectiveness simulation modeling studies, and implementation science studies—particularly relating to treatment of infectious diseases and substance use disorders. His current research includes economic evaluations of HIV and hepatitis C screening and treatment in substance use treatment settings, and economic evaluations of medication-assisted treatment of opioid use disorder.
Selected Publications
- Haynes LF, Korte JE, Holmes BE, Gooden L, Matheson T, Feaster DJ, Leff JA, Wilson L, Metsch LR, Schackman BR. HIV rapid testing in substance abuse treatment: Implementation following a clinical trial. Eval Program Plann. 2011 Nov;34(4):399-406. doi: 10.1016/j.evalprogplan.2011.02.007. PMID: 21367457; PMCID: PMC3124222. View Source
- Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV screening in the United States: What will it cost government discretionary and entitlement programs? A budget impact analysis. Value Health. 2010 Dec;13(8):893-902. doi: 10.1111/j.1524-4733.2010.00763.x. PMID: 20950323; PMCID: PMC2999642. View Source
- Gans J, Falco M, Schackman BR, Winters KC. An in-depth survey of the screening and assessment practices of highly regarded adolescent substance abuse treatment programs. J Child Adolesc Subst Abuse. 2010 Jan;19(1):33-47. doi: 10.1080/10678280903400578. PMID: 20209067; PMCID: PMC2832184. View Source
- Schackman BR, Dastur Z, Rubin DS, Berger J, Camhi E, Netherland J, Ni Q, Finkelstein R. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. AIDS Care. 2009 Aug;21(8):992-9. doi: 10.1080/09540120802657506. PMID: 20024755. View Source
- Teixeira PA, Schackman BR. Can urban methadone patients complete health utility assessments? Patient Educ Couns. 2008 May;71(2):302-7. doi: 10.1016/j.pec.2008.01.010. PMID: 18314295; PMCID: PMC2361157. View Source
- Schackman BR, Teixeira PA, Weitzman G, Mushlin AI, Jacobson IM. Quality-of-life tradeoffs for hepatitis C treatment: Do patients and providers agree? Med Decis Making. 2008 Mar-Apr;28(2):233-42. doi: 10.1177/0272989X07311753. PMID: 18349430. View Source
- Schackman BR, Dastur Z, Ni Q, Callahan MA, Berger J, Rubin DS. Sexually active HIV-positive patients frequently report never using condoms in audio computer-assisted self-interviews conducted at routine clinical visits. AIDS Patient Care STDS. 2008 Feb;22(2):123-9. doi: 10.1089/apc.2007.0037. PMID: 18260803. View Source
- Schackman BR, Rojas EG, Gans J, Falco M, Millman RB. Does higher cost mean better quality? Evidence from highly-regarded adolescent drug treatment programs. Subst Abuse Treat Prev Policy. 2007 Jul 31;2:23. doi: 10.1186/1747-597X-2-23. PMID: 17672900; PMCID: PMC1971258. View Source
- Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S247-53. doi: 10.1086/508190. PMID: 17109311. View Source
- Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov;44(11):990-7. doi: 10.1097/01.mlr.0000228021.89490.2a. PMID: 17063130. View Source
- Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L; Center for Adherence Support and Evaluation (case) Team. The cost of HIV medication adherence support interventions: Results of a cross-site evaluation. AIDS Care. 2005 Nov;17(8):927-37. doi: 10.1080/09540120500100635. PMID: 16265786. View Source
- Brannigan R, Schackman BR, Falco M, Millman RB. The quality of highly regarded adolescent substance abuse treatment programs: Results of an in-depth national survey. Arch Pediatr Adolesc Med. 2004 Sep;158(9):904-9. doi: 10.1001/archpedi.158.9.904. PMID: 15351757. View Source
- Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25;162(21):2478-86. doi: 10.1001/archinte.162.21.2478. PMID: 12437408. View Source
- Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001 Sep;91(9):1456-63. doi: 10.2105/ajph.91.9.1456. PMID: 11527782; PMCID: PMC1446805. View Source